African Vaccine Sovereignty: Wits Research Accelerates | AcademicJobs
Explore how Wits University's AGTRU is driving Africa's vaccine independence through mRNA platforms, viral mimics, and green lipids, amid the 60% local production goal by 2040.
No reviews yet. Be the first to rate Abdullah!
Abdullah Ely is an Associate Professor at the University of the Witwatersrand in the Faculty of Health Sciences. He completed his PhD at the Antiviral Gene Therapy Research Unit (AGTRU) in 2009, with doctoral research focused on exploiting the RNA interference pathway to silence hepatitis B virus replication. He holds MSc, BSc (Honours) and an additional MSc qualification from the University of the Witwatersrand. Ely serves as a team leader in AGTRU and has contributed to the development of novel gene therapy-based approaches to combat chronic hepatitis B virus infection as well as mRNA technologies for gene therapy and vaccines. He has been approved to assume leadership of AGTRU. His work centres on molecular biology applications in antiviral strategies.
Ely maintains an active research profile in gene therapy and related fields, with contributions to publications addressing antiviral interventions. He is affiliated with the Wits/SAMRC Antiviral Gene Therapy Research Unit and the Infectious Diseases and Oncology Research Institute.
Explore how Wits University's AGTRU is driving Africa's vaccine independence through mRNA platforms, viral mimics, and green lipids, amid the 60% local production goal by 2040.